



CME FOUNDATION OF INDIA



CHEST CONCLAVE

Chest Conclave

"**Chest Conclave**" was held on 29th & 30th June, 2024 at Evershine Resort & Spa, Mahabaleshwar. It was organized by the CME Foundation of India (CMEFI).

The sole objective of the was to bring leading KOLs amongst General Physician and Cardiologists on one platform and discuss their clinical experiences and expertise in the screening, treatment of Cardiological conditions.

The Introductory speech was given by CMEFI.

CMEFI emphasized the main role played by the CME Foundation of India and we all know how important it is to spread the knowledge known only to a select few to the practising doctors at large.

Date: 29th & 30th June, 2024

Venue: Evershine Resort & Spa, Mahabaleshwar

Total Participants: 11

Agenda

Date : 29th June, 2024

Time: 6:00 p.m. to 8:00 p.m.

Topic	Speaker	Timing
Lecture: Insights on approach to hypersecretory lung diseases: A clinician’s perspective Q & A	Speaker: Dr. Nitin Yashawant Abhyankar	6:00 p.m. to 7:00 p.m.
Real world: Challenges faced in the management of hypersecretory lung disease in Indian patients	Moderator: Dr. Shaikh Shoaib	7:00 p.m. to 8:00 p.m.

Summary of CME

- The CME conducted Chest Conclave in Evershine Resort & Spa, Mahabaleshwar. It was aimed to bring together well-known General Physician and Cardiologists on one platform and discuss their clinical experiences and expertise in the screening and treatment of Cardiological conditions.
- **CMEFI** welcomed the forum and shared a few thoughts on the topics that were on the agenda.
- **Insights on approach to hypersecretory lung diseases: A clinician's perspective - Dr. Nitin Yashawant Abhyankar**

Dr. Nitin Yashawant Abhyankar has provided comprehensive insights on the approach to managing hypersecretory lung diseases from a clinician's perspective. He explained in detail how these conditions, characterized by excessive mucus production, complicate respiratory function and patient management. Dr. Abhyankar emphasized the importance of thorough diagnostic evaluations, including advanced imaging and pulmonary function tests, to accurately assess the extent and impact of hypersecretion.

He discussed personalized treatment strategies that target the underlying causes of mucus overproduction, focusing on pharmacological therapies such as mucolytics and bronchodilators, alongside non-pharmacological interventions like pulmonary rehabilitation. Dr. Abhyankar highlighted the significance of patient education and adherence to treatment plans, underscoring the role of lifestyle modifications in managing these conditions. By integrating current research findings with practical clinical approaches, Dr. Abhyankar aims to optimize patient outcomes and improve quality of life for those suffering from hypersecretory lung diseases.

- **Challenges faced in the management of hypersecretory lung disease in Indian patients - Dr. Shaikh Shoaib**

Dr. Shaikh Shoaib has extensively detailed the challenges in managing hypersecretory lung disease among Indian patients. He explained that environmental factors, such as high levels of air pollution and widespread tobacco use, significantly exacerbate these conditions. Dr. Shoaib highlighted the difficulty in achieving early and accurate diagnosis due to limited access to advanced diagnostic tools like high-resolution imaging and pulmonary function tests, particularly in rural areas.

He highlighted the scarcity of specialized healthcare facilities and trained pulmonologists further complicates effective disease management. Socioeconomic factors also play a critical role, with many patients struggling to afford or adhere to prescribed treatments due to financial constraints. Dr. Shoaib emphasized the importance of developing personalized treatment plans that include both pharmacological therapies, such as mucolytics and bronchodilators, and non-pharmacological interventions, like pulmonary rehabilitation and lifestyle changes.

Dr. Shoaib discussed the need for comprehensive patient education programs to enhance awareness and ensure adherence to treatment regimens. Dr. Shoaib advocated for robust public health initiatives aimed at reducing exposure to environmental risk factors and improving healthcare infrastructure. By addressing these multifaceted challenges, he aims to enhance the management and outcomes of hypersecretory lung disease for Indian patients.

- Different cases were explained to the audience, and the entire case discussion focused on the complications and management of Cardiological conditions. The audience actively participated, engaging in a dynamic and interactive session. The delegates thoroughly enjoyed the opportunity to contribute to the discussion and share their insights on various aspects of Cardiological complications and their management.
- Participants were keen to share their experience and knowledge and they also provided their critiques and recommendations on the conclave.
- **In the end of this CME, the CME Foundation of India extended, its sincere vote of thanks to the attending delegates and acknowledged the academic industry partners for their valuable support and contribution to the success of this conclave.**

1. Cipla Ltd.

Snapshots of Chest Conclave


Welcome to the Chest Conclave




Registration Counter



Lecture on Insights on approach to hypersecretory lung diseases: A clinician's perspective



Discussion on Challenges faced in the management of hypersecretory lung disease in Indian patients



Q & A Session



Delight Attendees Through an Exceptional Conclave Experience



Branding Opportunity

